Abstract:Proteolysis-targeting chimeras (PROTACs) are hetero-bifunctional molecules. They induce the degradation of a target protein by recruiting an E3 ligase to the target. The PROTAC can inactivate disease-related genes that are considered as understudied, thus has a great potential to be a new type of therapy for the treatment of incurable diseases. However, only hundreds of proteins have been experimentally tested if they are amenable to the PROTACs. It remains elusive what other proteins can be targeted by the PROTAC in the entire human genome. For the first time, we have developed an interpretable machine learning model PrePROTAC, which is based on a transformer-based protein sequence descriptor and random forest classification to predict genome-wide PROTAC-induced targets degradable by CRBN, one of the E3 ligases. In the benchmark studies, PrePROTAC achieved ROC-AUC of 0.81, PR-AUC of 0.84, and over 40% sensitivity at a false positive rate of 0.05, respectively. Furthermore, we developed an embedding SHapley Additive exPlanations (eSHAP) method to identify positions in the protein structure, which play key roles in the PROTAC activity. The key residues identified were consistent with our existing knowledge. We applied PrePROTAC to identify more than 600 novel understudied proteins that are potentially degradable by CRBN, and proposed PROTAC compounds for three novel drug targets associated with Alzheimer's disease. Author summary: Many human diseases remain incurable because disease-causing genes cannot by selectively and effectively targeted by small molecules. Proteolysis-targeting chimera (PROTAC), an organic compound that binds to both a target and a degradation-mediating E3 ligase, has emerged as a promising approach to selectively target disease-driving genes that are not druggable by small molecules. Nevertheless, not all of proteins can be accommodated by E3 ligases, and be effectively degraded. Knowledge on the degradability of a protein will be crucial for the design of PROTACs. However, only hundreds of proteins have been experimentally tested if they are amenable to the PROTACs. It remains elusive what other proteins can be targeted by the PROTAC in the entire human genome. In this paper, we propose an intepretable machine learning model PrePROTAC that takes advantage of powerful protein language modeling. PrePROTAC achieves high accuracy when evaluated by an external dataset which comes from different gene families from the proteins in the training data, suggesting the generalizability of PrePROTAC. We apply PrePROTAC to the human genome, and identify more than 600 understudied proteins that are potentially responsive to the PROTAC. Furthermore, we design three PROTAC compounds for novel drug targets associated with Alzheimer's disease.

A Proteomic Platform to Identify Off-Target Proteins Associated with Therapeutic Modalities That Induce Protein Degradation or Gene Silencing

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeted Biomolecule Regulation Platform: A Split-and-Mix PROTAC Approach

High-throughput Drug Target Discovery Using a Fully Automated Proteomics Sample Preparation Platform.

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Chemical-Protein Interactome and Its Application in Off-Target Identification

Precise Modulation of Protein Degradation by Smart PROTACs

An overview of PROTACs: a promising drug discovery paradigm

Proteome-scale discovery of protein degradation and stabilization effectors

Elucidation of Genome-wide Understudied Proteins targeted by PROTAC-induced degradation using Interpretable Machine Learning

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Identifying The Proteins To Which Small-Molecule Probes And Drugs Bind In Cells

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation

Solvent-induced protein precipitation for drug target discovery on proteomic scale.

STREAMLINED PROTEOME-WIDE IDENTIFICATION OF DRUG TARGETS INDICATES ORGAN-SPECIFIC ENGAGEMENT

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Precipitate-Supported Thermal Proteome Profiling Coupled with Deep Learning for Comprehensive Screening of Drug Target Proteins